Vibeke Strand, MD
Vibeke Strand, MD, is a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. Dr Strand completed her undergraduate double major, with honors, in Zoology and Sociology/Anthropology at Swarthmore College, Pennsylvania. She then attended the University of California San Francisco School of Medicine and returned there to complete her subspecialty Rheumatology Fellowship after a Primary Care Internal Medicine Residency at Michigan State University.
Dr Strand has been a clinical rheumatologist for 35 years, in subspecialty practice in San Francisco, she has worked as as a clinical investigator and subsequently senior director of clinical research at 3 pharmaceutical/biotech companies. Dr Strand was an Assistant and Associate Clinical Professor at University of California San Francisco until 1993 when she then moved on to become Clinical Associate Professor in the Division of Immunology and Rheumatology at Stanford University. Since 2000 she has taught as an Adjunct Clinical Professor at Stanford University.
Since 1991, Dr Strand has led a consulting practice offering clinical research and regulatory expertise. Her focus is to help translate basic research into rational design of randomized controlled trials, evaluating their results and defending approval of novel products to the FDA and EMA. She has assisted in preparation of briefing documents, analyses and data presentation for defense of NDA and BLA applications in RA, SLE, PsA, SpA, SSc, uveitis, OA, gout and FMS.
Dr Strand established and co-chaired the biyearly “Innovative Therapies in Autoimmune Disease” meetings (1988–2007). She has served as a founding member of the Executive Organizing Committee of the international Outcomes in Rheumatology Clinical Trials (OMERACT) consensus conferences (1992–present). She helped establish and co-chaired the Clinical Immunology Society Spring Fellows School. She has been a member of the ACR RA Clinical Trials Task Force since 2011; Board of Directors and Medical and Scientific Committee of Northern California Chapter of the Arthritis Foundation since 2005; Board of Directors of CORRONA (2002–2008) and Scientific Advisory Board since 2010 and Board of Advisors for Analgesic Clinical Trial Innovations Opportunities and Networks (ACTTION) Public Private Partnership. She has been an invited speaker at FDA Arthritis Advisory Committee meetings discussing Guidance Documents for RA, OA, SLE, JIA, x-ray analyses in RA and outcome measures in pain, FMS and gout. Over the past 20 years she has participated in the development of all the approved biologic agents and synthetic DMARDs in RA, new therapies for PsA, SLE and OA and biosimilar monoclonal antibodies/soluble receptors. She has authored over 330 original publications and serves on the editorial board of multiple journals. She is a Fellow of the American College of Physicians (1982), Master of the American College of Rheumatology (2015), member of the Cosmos Club (1994) and it’s Substitute Board of Managers (2013–present).
Consultancy – AbbVie, Afferent, Alder, Amgen, Anthera, Asana, AstraZeneca, aTyr, Bayer, BiogenIdec, Biotest, Bioventus, BMS, Boehringer Ingelheim, Carbylan, Celgene, Celltrion, CORRONA, Crescendo, EMDSerono, Eupraxia, Flexion, Genentech/Roche, GlaxoSmithKline, Iroko, Janssen, Jazz Pharmaceuticals, Kezar, Kypha, Lilly, MerckSerono, Novartis, Pfizer, Protagen, Regeneron, Samsung, Samumed, Sandoz, Sanofi, SKK, Takeda, UCB, Vertex, XTL; Advisory Boards – AbbVie, Amgen, Anthera, AstraZeneca, Bayer, BiogenIdec, BMS, Carbylan, Crescendo, EMDSerono, Genentech/Roche, GSK, Horizon, Iroko, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Sandoz, Sanofi, Takeda, UCB